PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...
Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". Health Canada Grants Priority Review Designation for SUBLOCADE™ SLOUGH, ...
OAKLAND, Calif. — Dr. Andrew Herring has a clear goal walking into every appointment with patients seeking medication to treat an opioid use disorder: persuade them to get an injection of ...
RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback